and S.M.; task administration, T.Con. not really designated to take care of COVID-19 sufferers in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
and S.M.; task administration, T.Con. not really designated to take care of COVID-19 sufferers in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in